Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors
First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]
This article is featured on another website.
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company
Overview A US biotech company's Phase I oncology study had stalled under the management of…
Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company
Overview A US biotech company's Phase I oncology study had stalled under the management of…